AB-126-Chemo

AB-126-Chemo is an investigational neural-derived exosome therapy being developed by ArunA Biomedical for the treatment of chemotherapy-induced neuropathy. It is a specialized application of the company's proprietary AB-126 platform, which utilizes exosomes derived from human neural stem cells. These exosomes are designed to leverage natural intercellular communication pathways to deliver neuroprotective and regenerative signals to damaged neural tissues. The therapy aims to address the underlying neural damage caused by chemotherapeutic agents, potentially restoring function and reducing pain associated with peripheral neuropathy. As of early 2024, the program is in the discovery stage of development.

Other names

AB-126 for chemotherapy-induced neuropathyAB126 for chemotherapy-induced neuropathyAB 126 for chemotherapy-induced neuropathy